Rain Oncology's stock has fallen near 25% following postponement of milademetan's top-line results and increased net losses reported in Q4 2022 and the full year 2022. Investors may be concerned that ...
Rain Oncology is a late-stage oncology company. Their lead product, milademetan, is an oral inhibitor of the MDM2-p53. In the past, MDM2 inhibitors have been associated with severe hematologic events.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback